Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer

Area of Science:

• Oncology
• Cancer Biology
• Genetics

Background:

• Cancer cells exhibit DNA damage response (DDR) abnormalities, including cell cycle checkpoint and DNA repair defects.
• Synthetic lethality, targeting DDR pathways, is a successful cancer therapy paradigm, exemplified by PARP inhibitors for BRCA-mutated cancers.
• "BRCAness" broadens synthetic lethality strategies beyond BRCA pathway defects.

Purpose of the Study:

• To explore synthetic lethality strategies in pancreatic cancer.
• To investigate the role of DNA damage repair (DDR) gene mutations and epigenetic alterations in pancreatic cancer.
• To identify novel therapeutic avenues by combining epigenetic modifications with DDR inhibition.

Main Methods:

• Analysis of DNA damage repair (DDR) and cell cycle genes in human pancreatic cancer.
• Investigation of promoter region methylation in cell cycle and DDR genes.
• Review of preclinical and clinical trials involving combined DDR inhibitors and chemotherapeutic agents.

Main Results:

• Frequent mutations in cell cycle and DDR genes (P16, P73, APC, MLH1, ATM, PALB2, MGMT) were identified in pancreatic cancer.
• Promoter region methylation was frequently observed in cell cycle and DDR genes.
• Combined DDR inhibitors and chemotherapeutic agents are under investigation.

Conclusions:

• Aberrant epigenetic changes in cell cycle or DDR regulators represent a promising avenue for synthetic lethality strategies in pancreatic cancer.
• Epigenetic modifications complement Knudson's "hit" theory and the "BRCAness" concept in cancer therapy.
• Targeting epigenetic alterations in DDR pathways offers a novel approach for pancreatic cancer treatment.